AlphAIAlphAI — Financial news for AI agents
aol.comAUG 193 min read$PAVM

PAVmed (PAVM) Q2 2026 Earnings Call Transcript

PAVmed (PAVM) reported Q2 2026 GAAP net loss of $5.5M, non-GAAP adjusted loss of $1.7M, and revenue of $33K. Lucid Diagnostics revenue was $1.5M, driven by 2,770 EsoGuard tests. Cash balance was $3.8M. Veris Health aims for 1,000 patients in its registry. PortIO study showed 100% device patency, and FDA submission is targeted for early 2027. Octeris IRB approval is expected in October 2026. The company has $15M in senior secured notes maturing in 2029.

Original reporting
aol.com
Published Aug 19, 2026, 5:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
PAVmed (PAVM) Q2 2026 Earnings Call Transcript — source image
Source · aol.com
Decision brief

The 30-second read

$PAVMNeutralLow
01

Why it matters

The earnings release underscores cash burn and reliance on upcoming regulatory milestones, which may drive volatility.

02

Market read

Primary relevance to investors tracking early‑stage medical device and diagnostic companies; limited broader market effect.

03

What to watch

Potential cash infusion from the $32.5M callable warrants and upcoming senior note refinancing.

Relevance 6/10Novelty 8/10Timing: after earnings release

Background

PAVmed provided its Q2 2026 business update, detailing financial results and progress on its Veris health monitor, Lucid Diagnostics, and device pipelines.

Company-level read

Ticker impact

$PAVMNeutralMedium confidence
Context

Q2 2026 earnings call disclosed GAAP net loss of $5.5M, revenue of $33K, and updates on Veris, Lucid, and device pipelines.

Expected impact

Potential short-term downside pressure due to loss and low revenue; upside if FDA milestones are met.

Evidence & confidence

The company reported a loss and minimal revenue, indicating near‑term weakness, but the announced regulatory timelines could be a catalyst for a rebound.

Market effects

Sector

Highlights ongoing funding challenges in the med‑tech/diagnostics sector and the importance of FDA clearance paths.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact; primarily relevant to niche investors in early‑stage medical device companies.

Counterpoint

What could challenge this read

If FDA clearance is achieved on schedule, the stock could rally despite current losses.

Key entities

  • Company
    PAVmed Inc.

    NASDAQ‑listed med‑tech firm reporting Q2 2026 results.

  • Subsidiary
    Lucid Diagnostics

    Provides EsoGuard testing; contributes $1.5M revenue.

Read at source← All news

Related articles

AUG 15
$PAVMMed

PAVmed (PAVM) Q2 2026 Earnings Call Transcript

PAVmed (PAVM) held its Q2 2026 earnings call. GAAP net loss was $5.5 million ($0.87/share) and non-GAAP adjusted loss was $1.7 million ($0.27/share). Revenue was $33,000, with pro forma income over $3 million. Cash was $3.8 million at June 30. Management discussed Veris, Lucid Diagnostics, and device regulatory timelines, including a targeted early-2027 510(k) submission for Veris.

fool.com6 min
OCT 1
$PECOMed

Phillips Edison & Company Reaffirms Full Year 2026 Earnings Guidance; Increases Full Year 2026 Gross Acquisitions Guidance; Provides Investment Update

Phillips Edison & Company (PECO) reaffirmed its 2026 earnings guidance, expecting 6.3% year-over-year growth in Nareit FFO per diluted share. The company increased its 2026 gross acquisitions guidance to $600M-$700M and raised disposition expectations to $200M-$250M. PECO also announced $459.7M in year-to-date acquisitions and $174.0M in sales. Jeff Edison, CEO, highlighted the company's expanded joint venture with Northwestern Mutual and commitment to disciplined investing.

globenewswire.com2 min
OCT 1
$NKEHighAI 8/10

Nike stock sinks as revenue misses estimates, expects to cut jobs

Nike (NKE) reported fiscal Q1 revenue of $11.21B, missing estimates of $11.33B, and expects high single-digit revenue decline in fiscal 2027. EPS was $0.48, down from $0.49 YoY. The company plans job cuts to reduce costs. Gross margin expanded to 42.8%. CEO Elliott Hill acknowledged the uncertainty. Analyst Zach Warring noted valuations and expectations have been reset.

finance.yahoo.com2 min
OCT 1
$NKEMedAI 8/10

Nike CEO Warns of New Layoffs Next Year Amid Changing Operating Model

Nike CEO Elliott Hill announced changes to the company's operating model, including layoffs starting in 2027, as part of its 'Pace' strategy. The plan aims to streamline operations, reduce costs, and realign geographies, with expected savings of $2.5 billion by fiscal 2031. Nike reported Q1 2027 net income of $712 million, down 2% year-over-year, and net sales of $11.2 billion, down 4%.

wwd.com3 min